Results 181 to 190 of about 4,929,883 (200)

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Lancet, The, 2014
Edward B Garon, Oscar Arrieta, Tuncay Göksel   +2 more
exaly  

Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial

Lancet, The, 2019
Shammi L Ramlakhan, Carrol Gamble, Shrouk Messahel   +2 more
exaly  

Soledad Primera, Lines 1-61

MLN, 1973
openaire   +1 more source

Preserving Primary Care: the Front Line in the War Against Cancer

Ca-A Cancer Journal for Clinicians, 2007
exaly  

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

Lancet, The, 2013
Jyh-Ming Liou, Chieh-Chang Chen, Mei-Jyh Chen   +2 more
exaly  

Maintenance therapy after first‐line therapy for ovarian cancer: Quantitative effectiveness

Ca-A Cancer Journal for Clinicians
Stephanie Blank
exaly  

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

Lancet, The, 2012
Julia V Ershova, Charlotte Kvasnovsky, Laura E Via   +2 more
exaly  

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial

Ca-A Cancer Journal for Clinicians
Jianqing Zhu, Mo Chen, Ning Li
exaly  

Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

Lancet, The, 2016
Jyh-Ming Liou, Chieh-Chang Chen, Ming-Jong Bair   +2 more
exaly  

ระดับ LINE-1 methylation ต่ำลงในผู้ป่วยโรคเนื้องอกเนื้อเยื่ออ่อน

Chulalongkorn Medical Journal, 2018
openaire   +1 more source